Posted by Michael Wonder on 17 Apr 2020
Chi-Med announces surufatinib granted U.S. FDA fast track designations for the treatment of both pancreatic and non-pancreatic neuroendocrine tumours
17 April 2020 - Hutchison China MediTech today announces that the U.S. FDA has granted two fast track designations for the development of surufatinib, for the treatment of both advanced and progressive pancreatic neuroendocrine tumours and extra-pancreatic (non-pancreatic) neuroendocrine tumours in patients who are not amenable for surgery.
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor and fibroblast growth factor receptor, which both inhibit angiogenesis, and colony stimulating factor-1 receptor, which regulates tumour associated macrophages, promoting the body’s immune response against tumour cells. Its unique dual mechanism of action may be very suitable for possible combinations with other immunotherapies.
